ImageneBio, Inc. (IMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ImageneBio, Inc. (IMA) has a cash flow conversion efficiency ratio of -0.064x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.07 Million) by net assets ($142.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see IMA stock market capitalisation for the company's overall valuation and market capitalisation.
ImageneBio, Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how ImageneBio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
ImageneBio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ImageneBio, Inc. ranked by their cash flow conversion efficiency. Explore IMA cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Falcon Machine Tools Co Ltd
TWO:4513
|
-0.035x |
|
Eloxx Pharmaceuticals, Inc.
NASDAQ:ELOX
|
-0.103x |
|
Shan-Loong Transportation Co Ltd
TW:2616
|
-0.011x |
|
Sajo Oyang
KO:006090
|
0.010x |
|
TROPHY GAMES Development AS
CO:TGAMES
|
0.145x |
|
Park Elektrik Uretim Madencilik Sanayi ve Ticaret AS
IS:PRKME
|
0.001x |
|
Snow Lake Resources Ltd
NASDAQ:LITM
|
0.000x |
|
Gray Television Inc
NYSE:GTN-A
|
0.000x |
Annual Cash Flow Conversion Efficiency for ImageneBio, Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of ImageneBio, Inc. from 2018 to 2025. View ImageneBio, Inc. stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $133.14 Million | $-47.84 Million | -0.359x | +1.63% |
| 2024-12-31 | $125.93 Million | $-46.00 Million | -0.365x | +22.23% |
| 2023-12-31 | $169.76 Million | $-79.74 Million | -0.470x | +6.84% |
| 2022-12-31 | $146.97 Million | $-74.11 Million | -0.504x | -73.97% |
| 2021-12-31 | $207.88 Million | $-60.25 Million | -0.290x | -177.43% |
| 2020-12-31 | $-101.05 Million | $-37.83 Million | 0.374x | +148.01% |
| 2019-12-31 | $-61.46 Million | $47.93 Million | -0.780x | -407.93% |
| 2018-12-31 | $-45.84 Million | $-11.61 Million | 0.253x | -- |
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerl… Read more